List view / Grid view
8 August 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced the successful completion of the tender offer...
7 August 2012 | By Pfizer
U.S. agencies praise company’s cooperation and compliance program...
7 August 2012 | By GlaxoSmithKline
The European Commission has granted pazopanib marketing authorisation...
7 August 2012 | By Eli Lilly and Company
Eli Lilly and Company announced data from a Phase III trial...
7 August 2012 | By Abbott
The U.S. FDA has approved the Omnilink Elite® Vascular Balloon-Expandable Stent System...
6 August 2012 | By Pfizer
Bapineuzumab IV Phase 3 program discontinued...
6 August 2012 | By I Holland
I Holland were very pleased by the reaction to the launch of the 'Holland Die Condition Monitor'...
6 August 2012 | By Bristol-Myers Squibb Company
$1.6 million awarded in grants...
6 August 2012 | By Novartis
Collaboration to study CAR technology...
3 August 2012 | By GlaxoSmithKline
GlaxoSmithKline has completed its acquisition of Human Genome Sciences for US$3.6 billion...
3 August 2012 | By Pfizer
Phase 4 study has met its primary endpoint...
3 August 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announced an agreement with Servier & its partner XOMA Corporation...
3 August 2012 | By GlaxoSmithKline
GlaxoSmithKline announced regulatory submissions in the European Union and US...
Lonza has entered a worldwide, non-exclusive licensing agreement with iPS Academia Japan, Inc. for its induced pluripotent stem cell (iPSC) patent portfolio. By entering this agreement, Lonza demonstrates its commitment to the field of regenerative medicine and reinforces its belief that iPSCs are a key platform technology for the cell…
2 August 2012 | By Teva Pharmaceutical Industries Ltd
Dr. Carlo De Notaristefani appointed as President and CEO of Global Operations, and Mr. Aharon (Arik) Yaari as the Executive VP...
